SHARE PRICE > View All Stock Detailed Share Information Latest News Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70 Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study > View All News All News Upcoming Events October 29, 2026 Interim Management Statement Q3 2026 > View All Events All Events Latest Presentation October 29, 2026 Corporate Presentation – Q3 financials, October 2026 August 25, 2026 Corporate Presentation – Half-Year 2026 Financials May 12, 2026 Corporate Presentation – Q1 financials, May 2026 > View All Presentations All Presentations Latest Financial Documents October 29, 2026 Q3 Financial Statement 2026 August 25, 2026 H1 2026 Financial Statements May 12, 2026 Q1 Financial Statement 2026 > View All Reports All Annual Report Seth Lewis,EVP Corporate FinanceContact SethSTAY INFORMEDSubscribe to email alerts of your choosingSUBSCRIBEInstitutional investors: REQUEST 1-1 / CALLpowered by schedulR
Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
